Clemeprol is an antidepressant drug of the 3,3-diraylpropyl-amine type. It exhibits antireserpine activity in animal tests, inhibits the neuronal uptake of noradrenaline. The drug was used in the clinic for the treatment of depression in the 1980s, but no development was reported since.

Clamidoxic acid is a derivative of phenoxyacetic acid developed in the late 1950s by Smith and Nephew Research Ltd. Clamidoxic acid has been shown to have anti-inflammatory activity and low toxicity in animal tests. The compound was investigated in the clinical trials in patients suffering from rheumatoid arthritis and painful uncomplicated osteoarthritis of the hip, however, no further clinical development was reported.

Bithionol sulfoxide is an effective cestocide, and also used as a fasciolicide, usually in combination with other compounds because of its poor efficiency against immature flukes. It has also demonstrated efficacy in vitro as an antiprotozoal agent effective against species causing amoebic gill disease in fish. It has been used for veterinary applications but has more recently been superseded by modern anthelmintic drugs.

Levdobutamine is a beta-adrenoceptor agonist selective for the beta1-subtype. Levdobutamine was derived from dopamine. It is the active (S)-isomer of dobutamine. It is the cardiotonic agent.

Salethamide was developed as an anti-inflammatory agent to use as an analgesic. However, information about the further study of this compound is not available.

Tigestol is an Estrene derivative patented by Organon Laboratories Ltd. as an anabolic, androgenic, and progestative agent.

Octazamide an analgesic that was studied as an anti-inflammatory agent. Information about the current development of this compound is not available.

Ensaculin is related to naturally occurring benzopyranones like scoparone. The compound is a potent functional antagonist of excitatory amino acid-induced convulsions and mortality. In receptor-binding studies, Ensaculin showed high affinity to dopaminergic (D2, D3), serotoninergic (5-HT1A, 5-HT7), and adrenergic (A1a, A1b) receptors in the nanomolar range. Ensaculin antagonizes NMDA responses in a voltage-dependent manner. Various studies support the notion that this compound could indeed have a broad range of nootropic properties. Although few patients presented postural hypotension and dizziness after receiving ensaculin in phase I clinical trials, this drug candidate was further discontinued in phase III due to potential side effects.

Etazepine (5,6-dihydro-5-methyl-11H-11-ethoxy-dibenzo[b,e]azepin-6-one) demonstrates anticonvulsant activity in rodents. Etazepine seems to exert its anticonvulsant effects by activating the GABAergic system.